抗VEGF药物不良反应处理.ppt

* * Bevacizumab in first-line NSCLC: reference deck * * * Anti-VEGF therapy causes decreased production of the vasodilator NO, leading to vasoconstriction, increased peripheral resistance and hypertension1,2 Decreased VEGF activity contributes to the increase of systemic vascular resistance as a result of vascular rarefaction, downregulation of NO production and dysregulation of renal endothelial cells and podocyte VEGF expression leading to thrombotic microangiopathy and thereby hypertension2 References Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates ecNOS message, protein and NO pro